|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C16orf95 |
Gene summary for C16ORF95 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C16orf95 | Gene ID | 100506581 |
| Gene name | chromosome 16 open reading frame 95 | |
| Gene Alias | C16orf95 | |
| Cytomap | 16q24.2 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | H3BNZ7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100506581 | C16orf95 | LZE7T | Human | Esophagus | ESCC | 6.05e-07 | 5.58e-01 | 0.0667 |
| 100506581 | C16orf95 | P2T-E | Human | Esophagus | ESCC | 1.65e-06 | 8.41e-02 | 0.1177 |
| 100506581 | C16orf95 | P4T-E | Human | Esophagus | ESCC | 3.84e-10 | 2.54e-01 | 0.1323 |
| 100506581 | C16orf95 | P5T-E | Human | Esophagus | ESCC | 5.93e-05 | 1.37e-01 | 0.1327 |
| 100506581 | C16orf95 | P9T-E | Human | Esophagus | ESCC | 2.18e-15 | 4.24e-01 | 0.1131 |
| 100506581 | C16orf95 | P10T-E | Human | Esophagus | ESCC | 7.23e-19 | 5.17e-01 | 0.116 |
| 100506581 | C16orf95 | P12T-E | Human | Esophagus | ESCC | 9.60e-08 | 1.82e-01 | 0.1122 |
| 100506581 | C16orf95 | P15T-E | Human | Esophagus | ESCC | 4.33e-08 | 1.23e-01 | 0.1149 |
| 100506581 | C16orf95 | P16T-E | Human | Esophagus | ESCC | 5.15e-10 | 7.30e-02 | 0.1153 |
| 100506581 | C16orf95 | P21T-E | Human | Esophagus | ESCC | 5.83e-11 | 2.50e-01 | 0.1617 |
| 100506581 | C16orf95 | P22T-E | Human | Esophagus | ESCC | 6.84e-11 | 2.85e-01 | 0.1236 |
| 100506581 | C16orf95 | P26T-E | Human | Esophagus | ESCC | 2.19e-21 | 4.09e-01 | 0.1276 |
| 100506581 | C16orf95 | P27T-E | Human | Esophagus | ESCC | 1.96e-14 | 3.37e-01 | 0.1055 |
| 100506581 | C16orf95 | P28T-E | Human | Esophagus | ESCC | 3.26e-09 | 2.21e-01 | 0.1149 |
| 100506581 | C16orf95 | P30T-E | Human | Esophagus | ESCC | 2.34e-12 | 4.66e-01 | 0.137 |
| 100506581 | C16orf95 | P31T-E | Human | Esophagus | ESCC | 4.16e-16 | 3.90e-01 | 0.1251 |
| 100506581 | C16orf95 | P32T-E | Human | Esophagus | ESCC | 3.25e-04 | 1.13e-01 | 0.1666 |
| 100506581 | C16orf95 | P40T-E | Human | Esophagus | ESCC | 7.50e-04 | 1.76e-01 | 0.109 |
| 100506581 | C16orf95 | P48T-E | Human | Esophagus | ESCC | 9.98e-05 | 1.64e-01 | 0.0959 |
| 100506581 | C16orf95 | P52T-E | Human | Esophagus | ESCC | 1.11e-08 | 2.48e-01 | 0.1555 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C16orf95 | SNV | Missense_Mutation | novel | c.637C>T | p.Arg213Cys | p.R213C | protein_coding | tolerated(0.08) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| C16orf95 | SNV | Missense_Mutation | rs567528534 | c.197G>A | p.Arg66His | p.R66H | protein_coding | tolerated(0.17) | possibly_damaging(0.454) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| C16orf95 | SNV | Missense_Mutation | rs761836002 | c.680N>T | p.Pro227Leu | p.P227L | protein_coding | tolerated(1) | benign(0) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| C16orf95 | SNV | Missense_Mutation | novel | c.652N>A | p.Gly218Ser | p.G218S | protein_coding | tolerated(1) | benign(0.024) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C16orf95 | SNV | Missense_Mutation | rs567528534 | c.197N>A | p.Arg66His | p.R66H | protein_coding | tolerated(0.17) | possibly_damaging(0.454) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C16orf95 | SNV | Missense_Mutation | rs780555091 | c.562N>A | p.Gly188Ser | p.G188S | protein_coding | tolerated(0.62) | possibly_damaging(0.71) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| C16orf95 | SNV | Missense_Mutation | novel | c.8C>T | p.Ala3Val | p.A3V | protein_coding | tolerated_low_confidence(0.23) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C16orf95 | SNV | Missense_Mutation | novel | c.323G>T | p.Arg108Leu | p.R108L | protein_coding | deleterious(0.03) | benign(0.312) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD | |
| C16orf95 | SNV | Missense_Mutation | novel | c.203N>T | p.Ser68Leu | p.S68L | protein_coding | tolerated(0.19) | probably_damaging(0.927) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C16orf95 | SNV | Missense_Mutation | novel | c.451N>T | p.Pro151Ser | p.P151S | protein_coding | deleterious(0.04) | benign(0.031) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |